Avastin Breast Cancer Dispute Centers On “Magnitude Of Benefit” Questions

The decision on whether Avastin’s metastatic breast cancer indication should be retained may come down to three words – “magnitude of benefit.”

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet